Nalbuphine ER not checked

Trevi Therapeutics

FollowEvery change as it happens, and a Monday email
Stage
No active trials
 
Next date
None yet
 
Trials
0 active
2 in total

What this is

How it works
How it works isn't classified yet
Tested for
Prurigo Nodularis, Hepatic Impairment
Main trialPhase 2/3
“To investigate the anti-pruritic efficacy and safety of Nalbuphine Extended Release (ER) (NAL ER) tablets in Prurigo Nodularis. Participants were randomized to NAL ER (or matching placebo) with the primary endpoint evaluation at Week 14. During the open label extension, participants who received NAL ER were continued on NAL ER and participants who received placebo would then shift to NALER.”In the company’s words, NCT03497975 on ClinicalTrials.gov
Other names
NAL ER Tablets · NAL ER

Other drugs for Hepatic Impairment

All 20 drugs for Hepatic Impairment

Coming up0

No dates coming up.

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials2

TrialPhaseCompletesWhat it tests
Phase 2/3Completed 10 May 2022 PRISM Study-Pruritus Relief Through Itch Scratch Modulation
Phase 1Completed 5 Feb 2020 Study of Nalbuphine ER in Participants With Hepatic Impairment
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow Nalbuphine ER

Following is part of Solo: you see every change to Nalbuphine ER the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in